{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:47:01Z","timestamp":1792565221213,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PSMA PET\/CT plays an important role in biochemically recurrent prostate cancer (BCR-PCa). In general, PET\/CT is performed as a limited or true whole-body examination. The majority of PET\/CT scanners operate by measuring several bed positions or continuous motion with a limited axial field of view (FOV). Shortening the scan area thus results in a time saving, with unknown information loss regarding the detection of tumor manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      This retrospective single-center study included 200 patients with BCR-PCa after initial curative therapy who underwent a\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-PET\/CT scan from vertex to toe (true whole-body). Using retrospective subdivision into hypothetical partial body measurement protocols, the undetected tumor manifestations were examined. Classic PET\/CT protocols were used: vertex to mid-thigh, skull base to mid-thigh, as well as CT-equivalent examination areas: chest\/abdomen\/pelvis (CAP), abdomen\/pelvis (AP) and pelvis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 200 patients with a median PSA of 1.1 ng\/mL, 128 (64%) showed at least one structural correlate of BCR-PCa in the true whole-body scan. The overall detection rate did not change for limited classic PET-protocols, or CAP measurements. CAP scans would not have detected all tumor manifestations in 16 patients (8%) and not all tumor-affected organ systems in six patients (3%), AP scans in 41 patients (21%) and 18 patients (9%), pelvic scans in 61 patients (31%) and 37 patients (19%), respectively. PSA may contribute to the prospective restriction of the scan area. Patients with PSA\u2009\u2264\u20090.75 ng\/mL showed no diagnostic gain from whole-body imaging. This means that in 45% of patients in our cohort, a limitation to CAP scan would have been possible without losing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For a resource-saving use of routine PSMA-PET\/CT, a scan from the vertex to the mid-thigh seems sufficient for detecting relevant metastases. For patients with low PSA levels, a more focused protocol that includes only the CAP region can be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-026-02940-w","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:14:18Z","timestamp":1792563258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of reduced scan extent on tumor detection in 68Ga-PSMA PET\/CT for biochemical recurrence of prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Falk","family":"G\u00fchne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"K\u00fcppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Freesmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"1","key":"2940_CR1","doi-asserted-by":"publisher","first-page":"e2456825","DOI":"10.1001\/jamanetworkopen.2024.56825","volume":"8","author":"EL Van Blarigan","year":"2025","unstructured":"Van Blarigan EL, McKinley MA, Washington SL 3rd, Cooperberg MR, Kenfield SA, Cheng I, Gomez SL. Trends in Prostate Cancer Incidence and Mortality Rates. JAMA Netw Open. 2025;8(1):e2456825. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2940_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024;211(4):509\u201317. https:\/\/doi.org\/10.1097\/JU.0000000000003892.","journal-title":"J Urol"},{"issue":"4","key":"2940_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):518\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000003891.","journal-title":"J Urol"},{"issue":"2","key":"2940_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P van den Cornford","year":"2024","unstructured":"van den Cornford P, Van den Briers E, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"6","key":"2940_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1159\/000081343","volume":"27","author":"P Gassmann","year":"2004","unstructured":"Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie. 2004;27(6):577\u201382. https:\/\/doi.org\/10.1159\/000081343.","journal-title":"Onkologie"},{"issue":"2","key":"2940_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Thomson A, Chen DC, Cannoletta D, Quarta L, Pellegrino A, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis. Eur Urol. 2025;88(2):129\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.006.","journal-title":"Eur Urol"},{"issue":"6","key":"2940_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bju.15052","volume":"125","author":"TH Huits","year":"2020","unstructured":"Huits TH, van der Luiting HB, Nandurkar R, Donswijk M, Schaake E, et al. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ((68) Ga-PSMA) positron-emission\/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection. BJU Int. 2020;125(6):876\u201383. https:\/\/doi.org\/10.1111\/bju.15052.","journal-title":"BJU Int"},{"issue":"2","key":"2940_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jmir.2024.01.012","volume":"55","author":"N Bower","year":"2024","unstructured":"Bower N, Morris A, O\u2019Connor J, Sponagle M, Bahr R, Gilbert R, et al. Clinical value of whole body (18)F-FDG PET\/CT imaging in patients with cutaneous melanoma: A multi-center cohort study. J Med Imaging Radiat Sci. 2024;55(2):212\u201320. https:\/\/doi.org\/10.1016\/j.jmir.2024.01.012.","journal-title":"J Med Imaging Radiat Sci"},{"issue":"6","key":"2940_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/a-1542-6064","volume":"60","author":"LF Stolzenbach","year":"2021","unstructured":"Stolzenbach LF, Locherbach F, Wargenau K, Pose R, Steuber T, Tian Z, et al. Clinical impact of whole-body 68Ga-PSMA I&T PET\/CT: lesion frequency and added benefit in lower extremities. Nuklearmedizin. 2021;60(6):417\u201324. https:\/\/doi.org\/10.1055\/a-1542-6064.","journal-title":"Nuklearmedizin"},{"issue":"5","key":"2940_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2940_CR11","doi-asserted-by":"publisher","unstructured":"G\u00fchne F, Radke S, Winkens T, Kuhnel C, Greiser J, Seifert P, et al. Differences in distribution and detection rate of the [\u2076\u2078Ga]Ga-PSMA ligands PSMA-617, -I&T and \u2013 11-inter-individual comparison in patients with biochemical relapse of prostate cancer. Pharmaceuticals (Basel). 2021;15(1). https:\/\/doi.org\/10.3390\/ph15010009.","DOI":"10.3390\/ph15010009"},{"key":"2940_CR12","doi-asserted-by":"publisher","unstructured":"Annunziata S, Pizzuto DA, Treglia G. Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses. Cancers (Basel). 2020;12(8). https:\/\/doi.org\/10.3390\/cancers12082153.","DOI":"10.3390\/cancers12082153"},{"issue":"8","key":"2940_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u201368. https:\/\/doi.org\/10.1007\/s00259-017-3711-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2940_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13014-018-0983-4","volume":"13","author":"NS Schmidt-Hegemann","year":"2018","unstructured":"Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, et al. Outcome after PSMA PET\/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol. 2018;13(1):37. https:\/\/doi.org\/10.1186\/s13014-018-0983-4.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2940_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","volume":"24","author":"S Harsini","year":"2024","unstructured":"Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, et al. Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer. Cancer Imaging. 2024;24(1):117. https:\/\/doi.org\/10.1186\/s40644-024-00752-1.","journal-title":"Cancer Imaging"},{"key":"2940_CR16","doi-asserted-by":"publisher","first-page":"929444","DOI":"10.3389\/fonc.2022.929444","volume":"12","author":"M Alberto","year":"2022","unstructured":"Alberto M, Yim A, Papa N, Siva S, Ischia J, Touijer K, et al. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol. 2022;12:929444. https:\/\/doi.org\/10.3389\/fonc.2022.929444.","journal-title":"Front Oncol"},{"issue":"4","key":"2940_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12149-014-0814-0","volume":"28","author":"S Kawata","year":"2014","unstructured":"Kawata S, Imaizumi M, Kako Y, Oku N. Clinical impact of true whole-body (18)F-FDG PET\/CT: lesion frequency and added benefit in distal lower extremities. Ann Nucl Med. 2014;28(4):322\u20138. https:\/\/doi.org\/10.1007\/s12149-014-0814-0.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"2940_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/0284185113476021","volume":"54","author":"R Sebro","year":"2013","unstructured":"Sebro R, Mari-Aparici C, Hernandez-Pampaloni M. Value of true whole-body FDG-PET\/CT scanning protocol in oncology: optimization of its use based on primary diagnosis. Acta Radiol. 2013;54(5):534\u20139. https:\/\/doi.org\/10.1177\/0284185113476021.","journal-title":"Acta Radiol"},{"issue":"6","key":"2940_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2214\/AJR.09.3731","volume":"195","author":"MM Osman","year":"2010","unstructured":"Osman MM, Chaar BT, Muzaffar R, Oliver D, Reimers HJ, Walz B, Nguyen NC. 18F-FDG PET\/CT of patients with cancer: comparison of whole-body and limited whole-body technique. AJR Am J Roentgenol. 2010;195(6):1397\u2013403. https:\/\/doi.org\/10.2214\/AJR.09.3731.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"2940_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MNM.0000000000000778","volume":"39","author":"HR Webb","year":"2018","unstructured":"Webb HR, Latifi HR, Griffeth LK. Utility of whole-body (head-to-toe) PET\/CT in the evaluation of melanoma and sarcoma patients. Nucl Med Commun. 2018;39(1):68\u201373. https:\/\/doi.org\/10.1097\/MNM.0000000000000778.","journal-title":"Nucl Med Commun"},{"issue":"8","key":"2940_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2967\/jnumed.118.222299","volume":"60","author":"JJ Cerci","year":"2019","unstructured":"Cerci JJ, Etchebehere EC, Nadel H, Brink A, Bal CS, Rangarajan V, et al. Is True Whole-Body (18)F-FDG PET\/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective Study. J Nucl Med. 2019;60(8):1087\u201393. https:\/\/doi.org\/10.2967\/jnumed.118.222299.","journal-title":"J Nucl Med"},{"issue":"9","key":"2940_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/MNM.0b013e32827420cc","volume":"28","author":"RD Niederkohr","year":"2007","unstructured":"Niederkohr RD, Rosenberg J, Shabo G, Quon A. Clinical value of including the head and lower extremities in 18F-FDG PET\/CT imaging for patients with malignant melanoma. Nucl Med Commun. 2007;28(9):688\u201395. https:\/\/doi.org\/10.1097\/MNM.0b013e32827420cc.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"2940_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1967\/s002449910055","volume":"15","author":"JC Tan","year":"2012","unstructured":"Tan JC, Chatterton BE. Is there an added clinical value of truewhole body(18)F-FDG PET\/CT imaging in patients with malignant melanoma? Hell J Nucl Med. 2012;15(3):202\u20135. https:\/\/doi.org\/10.1967\/s002449910055.","journal-title":"Hell J Nucl Med"},{"issue":"9","key":"2940_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/MNM.0b013e32833cb8b7","volume":"31","author":"S Querellou","year":"2010","unstructured":"Querellou S, Keromnes N, Abgral R, Sassolas B, Le Roux PY, Cavarec MB, et al. Clinical and therapeutic impact of 18F-FDG PET\/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nucl Med Commun. 2010;31(9):766\u201372. https:\/\/doi.org\/10.1097\/MNM.0b013e32833cb8b7.","journal-title":"Nucl Med Commun"},{"key":"2940_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.25259\/JCIS_93_2020","volume":"10","author":"S Ozdemir","year":"2020","unstructured":"Ozdemir S, McCook B, Klassen C. Whole-Body versus Routine Skull Base to Mid-thigh (18)F-Fluorodeoxyglucose Positron Emission Tomography\/ Computed Tomography in Patients with Malignant Melanoma. J Clin Imaging Sci. 2020;10:47. https:\/\/doi.org\/10.25259\/JCIS_93_2020.","journal-title":"J Clin Imaging Sci"},{"issue":"1","key":"2940_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/1754-9485.13797","volume":"69","author":"CT Cheng","year":"2025","unstructured":"Cheng CT, Lee S, Ahmad K, Ma D. Frequency and clinical implications of findings on true whole-body 18F-FDG PET in the assessment of breast cancer. J Med Imaging Radiat Oncol. 2025;69(1):17\u201320. https:\/\/doi.org\/10.1111\/1754-9485.13797.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"3","key":"2940_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2967\/jnmt.118.224303","volume":"47","author":"DH Simsek","year":"2019","unstructured":"Simsek DH, Sanli Y, Kuyumcu S, Engin MN, Buyukkaya F, Demirci E. Clinical Impact of Lower-Limb Imaging in (68)Ga-PSMA PET\/CT for Patients with Prostate Cancer. J Nucl Med Technol. 2019;47(3):233\u20137. https:\/\/doi.org\/10.2967\/jnmt.118.224303.","journal-title":"J Nucl Med Technol"},{"issue":"3","key":"2940_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2967\/jnumed.119.230318","volume":"61","author":"KL Pomykala","year":"2020","unstructured":"Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-Body (68)Ga-PSMA-11 PET\/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020;61(3):405\u201311. https:\/\/doi.org\/10.2967\/jnumed.119.230318.","journal-title":"J Nucl Med"},{"issue":"1","key":"2940_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00259-016-3532-0","volume":"44","author":"M Spadafora","year":"2017","unstructured":"Spadafora M, Pace L, Mansi L. Segmental (18)F-FDG-PET\/CT in a single pulmonary nodule: a better cost\/effectiveness strategy. Eur J Nucl Med Mol Imaging. 2017;44(1):1\u20134. https:\/\/doi.org\/10.1007\/s00259-016-3532-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2940_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejrad.2017.03.001","volume":"90","author":"M Spadafora","year":"2017","unstructured":"Spadafora M, Evangelista L, Gridelli C, Cuocolo A. Alternative imaging strategy of solitary pulmonary nodule by FDG PET\/CT: Can be imagined a tailored PET? Eur J Radiol. 2017;90:188\u201391. https:\/\/doi.org\/10.1016\/j.ejrad.2017.03.001.","journal-title":"Eur J Radiol"},{"issue":"2","key":"2940_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1754-9485.13164","volume":"65","author":"F G\u00fchne","year":"2021","unstructured":"G\u00fchne F, Drescher R, Seifert P, Freesmeyer M. Supplemental minimal-activity PET\/CT to validate ambiguous findings with less than 1 mSv: Proof of concept. J Med Imaging Radiat Oncol. 2021;65(2):201\u20137. https:\/\/doi.org\/10.1111\/1754-9485.13164.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"5","key":"2940_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1055\/a-0985-3954","volume":"58","author":"F G\u00fchne","year":"2019","unstructured":"G\u00fchne F, Drescher R, Seifert P, Freesmeyer M. Minimal-activity PET\/CT for efficacy control after SIRT (MAPECSI) - clinical implementation of a resource-saving, liver-focused protocol. Nuklearmedizin. 2019;58(5):363\u201370. https:\/\/doi.org\/10.1055\/a-0985-3954.","journal-title":"Nuklearmedizin"},{"issue":"3","key":"2940_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18383\/j.tom.2020.00030","volume":"6","author":"F G\u00fchne","year":"2020","unstructured":"G\u00fchne F, Drescher R, Aschenbach R, Seifert P, Freesmeyer M. Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET\/CT. Tomography. 2020;6(3):288\u20139. https:\/\/doi.org\/10.18383\/j.tom.2020.00030.","journal-title":"Tomography"},{"key":"2940_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euros.2025.10.020","volume":"82","author":"M Demirbilek","year":"2025","unstructured":"Demirbilek M, Kalender G, Biyikoglu S, Asa S, Akkus E, Gurses I, et al. External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography-based PRIMARY Score. Eur Urol Open Sci. 2025;82:170\u20137. https:\/\/doi.org\/10.1016\/j.euros.2025.10.020.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"2940_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-016-3511-5","volume":"44","author":"R Hustinx","year":"2017","unstructured":"Hustinx R. How to scan who: the delicate balance between selecting the patient and selecting the imaging protocol. Eur J Nucl Med Mol Imaging. 2017;44(1):5\u20137. https:\/\/doi.org\/10.1007\/s00259-016-3511-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2940_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40644-024-00693-9","volume":"24","author":"OU Kolade","year":"2024","unstructured":"Kolade OU, Brink A, Ayeni AO, More S, Holness J. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study. Cancer Imaging. 2024;24(1):46. https:\/\/doi.org\/10.1186\/s40644-024-00693-9.","journal-title":"Cancer Imaging"},{"issue":"4","key":"2940_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s13246-017-0596-5","volume":"40","author":"T Umeda","year":"2017","unstructured":"Umeda T, Miwa K, Murata T, Miyaji N, Wagatsuma K, Motegi K, et al. Optimization of a shorter variable-acquisition time for legs to achieve true whole-body PET\/CT images. Australas Phys Eng Sci Med. 2017;40(4):861\u20138. https:\/\/doi.org\/10.1007\/s13246-017-0596-5.","journal-title":"Australas Phys Eng Sci Med"},{"key":"2940_CR38","doi-asserted-by":"publisher","first-page":"111873","DOI":"10.1016\/j.ejrad.2024.111873","volume":"183","author":"GJR Cook","year":"2025","unstructured":"Cook GJR, Alberts IL, Wagner T, Fischer BM, Nazir MS, Lilburn D. The impact of long axial field of view (LAFOV) PET on oncologic imaging. Eur J Radiol. 2025;183:111873. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111873.","journal-title":"Eur J Radiol"},{"issue":"1","key":"2940_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.semnuclmed.2024.05.008","volume":"55","author":"A Dimitrakopoulou-Strauss","year":"2025","unstructured":"Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Total Body PET-CT Protocols in Oncology. Semin Nucl Med. 2025;55(1):3\u201310. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.05.008.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"2940_CR40","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00259-024-06968-4","volume":"52","author":"G Liu","year":"2025","unstructured":"Liu G, Gu Y, Sollini M, Lazar A, Besson FL, Li S, et al. Expert consensus on workflow of PET\/CT with long axial field-of-view. Eur J Nucl Med Mol Imaging. 2025;52(3):1038\u201349. https:\/\/doi.org\/10.1007\/s00259-024-06968-4.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02940-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:26:16Z","timestamp":1792563976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02940-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02940-w","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was registered and approved by the local Ethics committee of the Friedrich-Schiller-University Jena under the registration number 2021-2209-Daten allowing retrospective analysis of clinical data. All experiments were performed in accordance with the Declaration of Helsinki. The patients gave written informed consent for the clinically indicated examinations performed.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No identifying information are published.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"535"}}